Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 6/20 | 0.39 |
| ▸ | CDC25B | P30305 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | EBP | Q15125 | 3/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405712 | 0.86 | CDC25B (0.49) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9769618 | 0.84 | USP2 (0.40) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9769598 | 0.84 | USP2 (0.40) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL6704985 | 0.80 | CRYAB (0.48) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL6405681 | 0.79 | USP2 (0.38) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9769590 | 0.79 | USP2 (0.38) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9644065 | 0.78 | MAPT (0.45) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9644062 | 0.78 | MAPT (0.45) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9766769 | 0.78 | MAPT (0.48) | USP2ALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL9766774 | 0.78 | MAPT (0.48) | USP2ALDH1A1CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222098-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| US-5716777-A | REGULATING MEIOSIS IN MAMMALIAN GERM CELL BY ADMINISTERING SPECIFIED STEROL IN VITRO | NOVO NORDISK A/S (DK) | 1998-02-10 | — | — | US | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222098-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | USP2 2491/4885ALDH1A1 2659/4885CYP3A4 3932/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | USP2 2491/4885ALDH1A1 2659/4885CYP3A4 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.